Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Hybridoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    17 result(s) found for: Hybridoma. Displaying page 1 of 1.
    EudraCT Number: 2009-014076-22 Sponsor Protocol Number: IP-CAT-AC-04 Start Date*: 2009-09-23
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase II open label study to evaluate the safety of a second i.p. infusion cycle of catumaxomab in patients with malignant ascites due to carcinoma, requiring their first therapeutic puncture after...
    Medical condition: Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Ongoing) ES (Ongoing) IT (Completed) BE (Completed) SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001557-17 Sponsor Protocol Number: IP-CAT-AC-03 Start Date*: 2008-12-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized, open-label, phase IIIb study investigating the safety of a 3 hour i.p. infusion of catumaxomab with and without prednisolone premedication in patients with malignant ascites du...
    Medical condition: malignant ascites
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025538 Malignant ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) FR (Ongoing) BE (Ongoing) GB (Completed) SE (Completed) NL (Ongoing) DK (Completed) PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000723-15 Sponsor Protocol Number: IP-REM-AC-01 inc. A1,D1,2,3,4,5; Start Date*: 2004-11-15
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Two-arm, randomized (2:1), open-label phase II/III study in EpCAM positive cancer patients with symptomatic malignant ascites using paracentesis plus the tri-functional antibody removab (anti-EpCAM...
    Medical condition: Cancer : Malignant Ascites
    Disease: Version SOC Term Classification Code Term Level
    8.1 10025538 Malignant ascites LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) LT (Completed) GB (Completed) EE (Completed) LV (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014641-88 Sponsor Protocol Number: STP-LYM-01-V01 Start Date*: 2010-01-14
    Sponsor Name:Medizinische Fakultaet der Technischen Universitaet Muenchen
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in combination with donor lymphocyte infusion (DLI) in patients with CD20 posit...
    Medical condition: CD20 positive chronic lymphocytic leukemia (CLL) low and high grade non-Hodgkin´s lymphoma (NHL)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-002727-16 Sponsor Protocol Number: IP-CAT-GC-03 Start Date*: 2007-03-06
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, open-label phase II study to evaluate the safety and efficacy of the tri-functional bispecific antibody catumaxomab (anti-EpCAM x anti-CD3) in patients with gastric adenocarcinoma afte...
    Medical condition: Gastric Neoplasm malignant
    Disease: Version SOC Term Classification Code Term Level
    15.0 10017947 - Gastrointestinal disorders 10017812 Gastric neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005945-20 Sponsor Protocol Number: IP-REM-GC-02 Start Date*: 2006-06-08
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, open-label and randomized phase II study to evaluate safety and efficacy of the tri-functional bispecific antibody catumaxomab(anti-EpCAM x anti-CD3) in patients after curative resecti...
    Medical condition: Advanced gastric adenocarcinoma and intended curative gastrectomy (R0 resection).
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017812 Gastric neoplasms malignant HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-001700-39 Sponsor Protocol Number: IP-REM-PK-01-EU Start Date*: 2005-09-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Determination of systemic exposure and characterization of pharmacokinetics of the tri-functional antibody catumaxomab (anti-EpCAM X anti-CD3) administered intraperitoneally in EpCAM positive cance...
    Medical condition: epithelial cell adhesion molecule (EpCAM) expressing tumors in patients with malignant ascites requiring therapeutic ascites puncture
    Disease: Version SOC Term Classification Code Term Level
    9.1 10025538 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004585-15 Sponsor Protocol Number: Cat-Ovar_2011 Start Date*: 2012-11-29
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Single –arm, multicenter phase-II trial for catumaxomab and chemotherapy in patients with recurrent ovarian cancer to investigate the feasibility and clinical activity of initial intraperitoneal ca...
    Medical condition: This is an international, explorative, open-label, prospective, non-randomized multicenter phase II study to assess the feasibility and clinical activity of initial intraperitoneal catumaxomab foll...
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    Population Age: Adults Gender: Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004294-21 Sponsor Protocol Number: FBT-IVREXBC 02 Start Date*: 2006-03-14
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase II study of the trifunctional anti-HER-2/neu x anti-CD3 antibody ertumaxomab for hormone therapy refractory patients with HER-2/neu 1+ or 2+ expressing advanced or metastatic breast cancer
    Medical condition: Hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express HER-2/neu (1+ or 2+)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed) ES (Completed) IT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006694-24 Sponsor Protocol Number: IV-A05-LL-01-PR.03 Start Date*: 2007-07-16
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase I/II dose-escalation study of the investigational trifunctional bispecific anti-CD20 x anti-CD3 antibody FBTA05 in relapsed or refractory chronic lymphocytic leukemia
    Medical condition: relapsed or refractory Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008976 Chronic lymphocytic leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001267-63 Sponsor Protocol Number: SIOPENRNET001 Start Date*: 2005-07-15
    Sponsor Name:St. Anna Kinderspital
    Full Title: Bridging study using ch14.18/CHO antibody in children with refractory neuroblastoma
    Medical condition: neuroblastoma
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004484-54 Sponsor Protocol Number: IP-CAT-OC-02 Start Date*: 2007-08-30
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Multicenter, single-arm, phase II study of the tri functional antibody catumaxomab (anti EpCAM x anti-CD3) administered intra- and postoperatively in patients with epithelial ovarian cancer
    Medical condition: Epithelial Ovarian Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033162 Ovarian epithelial cancer stage II LLT
    9.1 10033163 Ovarian epithelial cancer stage III LLT
    9.1 10033164 Ovarian epithelial cancer stage IV LLT
    9.1 10033161 Ovarian epithelial cancer stage I LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-012136-33 Sponsor Protocol Number: IPH2101-201 Start Date*: 2009-07-08
    Sponsor Name:Innate Pharma
    Full Title: Open randomised phase II study evaluating the anti-tumour activity, safety and pharmacology of two different dose regimens of IPH 2101, a human monoclonal anti-KIR antibody, in patients with multip...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-019395-73 Sponsor Protocol Number: CPJMR0012201 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyal...
    Medical condition: polymyalgia rheumatica
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10036099 Polymyalgia rheumatica PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005017-36 Sponsor Protocol Number: IV-ERT-BC-03 Start Date*: 2007-01-19
    Sponsor Name:Fresenius Biotech GmbH
    Full Title: Phase II study for repeated dosing of the trifunctional bispecific anti-HER-2/neu x anti-CD3 antibody ertumaxomab in patients with HER-2/neu 1+ or 2+/FISH negative expressing advanced or metastat...
    Medical condition: Hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV), which are known to express HER-2/neu (1+ or 2+) and are FISH negative.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006201 Breast cancer stage III LLT
    9.1 10006202 Breast cancer stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: AT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) FR (Ongoing) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015740-42 Sponsor Protocol Number: UKER00109STUM3 Start Date*: 2010-05-12
    Sponsor Name:Universitätsklinkum Erlangen
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN, PROSPECTIVE, CONTROLLED, PARALLEL-GROUP STUDY OF REDUCTION OF THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ONGOING REMISSION RETRO – REduction of Ther...
    Medical condition: Rheumatoid arthritis
    Disease: Version SOC Term Classification Code Term Level
    17.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-024111-13 Sponsor Protocol Number: AIO-STO-0110 Start Date*: 2011-04-15
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Explorative trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric adenocarcinomas prior to gastrectomy
    Medical condition: Gastric adenocarcinoma and carcinoma of the esophago-gastric junction (type II and type III according to Siewert’s classification) prior to gastrectomy, with peritoneal carcinomatosis.
    Disease: Version SOC Term Classification Code Term Level
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015362 Esophageal cancer LLT
    15.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068069 Peritoneal carcinomatosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 21:44:57 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA